Jun 01, 2021
Starpharma (ASX:SPL) shows 98pc antiviral activity against U.K COVID-19 variant
The Market Herald reports on Starpharma's latest announcement: "Starpharma (SPL) has confirmed that its SPL7013 drug has potent antiviral activity against the U.K. SARS-CoV-2 variant.
"In laboratory studies, SPL7013 achieved a reduction of more than 98 per cent against the virus."
Read the full article here.